Despite an uncertain funding environment, new 35 North research finds that kicking off new capital project initiatives is a top priority for 87% of life sciences organizations in the next 6-12 months.

The 2023 State of Life Sciences Capital Project Development details the priorities, pain points, and perceptions of over 300 project owners in the pharma, biotech, cell and gene therapy, and AgTech industries, breaking down:

• The primary risks associated with new capital developments
• The role of owner’s reps in mitigating capital project complexity
• Capital project plans for 2024 and beyond

Access the report to learn more about the current and future state of life sciences capital project development, and who project owners are relying on to help them navigate both.

View a summary of the report on our Insights blog: The Future of Life Sciences Capital Projects Presents Risks and Rewards